Published in J Urol on April 01, 2004
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Senescence-associated exosome release from human prostate cancer cells. Cancer Res (2008) 1.78
Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr (2012) 1.49
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol (2010) 1.47
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res (2011) 1.38
Robotic assistance for ultrasound-guided prostate brachytherapy. Med Image Anal (2008) 1.32
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). BMC Cancer (2007) 1.14
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer (2011) 1.04
Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer (2015) 1.02
Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr (2009) 1.01
Geriatric considerations in the treatment of advanced prostate cancer. F1000Prime Rep (2014) 0.95
Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer (2010) 0.95
Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res (2011) 0.95
Intra-operative 3D guidance and edema detection in prostate brachytherapy using a non-isocentric C-arm. Med Image Anal (2010) 0.93
Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat (2010) 0.92
Intraoperative 3D reconstruction of prostate brachytherapy implants with automatic pose correction. Phys Med Biol (2011) 0.91
Active surveillance or active treatment in localized prostate cancer? Dtsch Arztebl Int (2009) 0.91
Single positive core prostate cancer in a 12-core transrectal biopsy scheme: clinicopathological implications compared with multifocal counterpart. Korean J Urol (2010) 0.91
Development of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic medical record system. Prostate Int (2013) 0.89
Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer (2013) 0.88
The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol (2016) 0.88
Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. Open Prost Cancer J (2013) 0.87
Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol (2010) 0.85
The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl (2010) 0.85
Managing the low-socioeconomic-status prostate cancer patient. J Natl Med Assoc (2006) 0.85
Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol (2008) 0.83
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch (2014) 0.81
Optimizing postoperative sexual function after radical prostatectomy. Ther Adv Urol (2012) 0.80
Can erectile function be predicted after prostate cancer treatment? Asian J Androl (2011) 0.80
The Establishment of K-CaP (the Multicenter Korean Prostate Cancer Database). Korean J Urol (2013) 0.80
Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™. J Urol (2013) 0.78
Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists. PLoS One (2013) 0.78
Addressing the needs of the high-risk prostate cancer patient. Rev Urol (2005) 0.78
Interpreting patient-reported urinary and sexual function outcomes across multiple validated instruments. J Urol (2017) 0.77
Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. BMC Res Notes (2016) 0.77
A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. BMC Cancer (2016) 0.77
Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biol Ther (2007) 0.77
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Can Urol Assoc J (2009) 0.76
Clinical trials: nationally representative data in urology. Nat Rev Urol (2009) 0.75
More judicious use of expectant management for localized prostate cancer over the past two decades. J Urol (2016) 0.75
Survival following primary androgen deprivation therapy among men with localized prostate cancer. Indian J Urol (2008) 0.75
Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLoS One (2017) 0.75
Danish Prostate Cancer Registry - methodology and early results from a novel national database. Clin Epidemiol (2016) 0.75
Weighing the risks: prostate cancer versus cardiovascular disease. Rev Urol (2008) 0.75
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg (2003) 7.95
Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ (2002) 6.98
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol (2003) 4.11
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer (2007) 3.92
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol (2002) 3.14
Regression of low-grade squamous intra-epithelial lesions in young women. Lancet (2004) 2.98
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med (2004) 2.82
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
The economic impact of chronic prostatitis. Arch Intern Med (2004) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med (2008) 2.66
Spirituality influences health related quality of life in men with prostate cancer. Psychooncology (2006) 2.65
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med (2004) 2.64
Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer (2010) 2.61
Effectiveness of disease management programs in depression: a systematic review. Am J Psychiatry (2003) 2.60
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
A systematic review of diabetes disease management programs. Am J Manag Care (2005) 2.46
Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol (2003) 2.44
Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol (2005) 2.41
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
Diffusion of surgical innovation among patients with kidney cancer. Cancer (2008) 2.38
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst (2009) 2.28
Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst (2010) 2.17
Comorbidity and competing risks for mortality in men with prostate cancer. Cancer (2011) 2.17
Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology (2009) 2.16
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis. Cancer (2014) 2.07
Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. Cancer (2014) 2.06
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol (2006) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer (2009) 1.95
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90